Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

NCT03521570 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

RADIATION: IMRT
BIOLOGICAL: Nivolumab

Sponsor

Emory University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]